Table 1 Demographic data and clinical characteristics before and after propensity score matching
Variables | Original cohort | Matched cohort | ||||
|---|---|---|---|---|---|---|
nCRT (n = 97) | Non-nCRT (n = 116) | P | nCRT (n = 83) | Non-nCRT (n = 83) | P | |
Age (years, mean ± SD) | 55.0 ± 11.8 | 57.6 ± 11.1 | 0.097 | 55.6 ± 11.5 | 57.3 ± 11.2 | 0.358 |
Gender | 0.650 | 0.874 | ||||
Male | 59 (60.8) | 67 (57.7) | 50 (60.2) | 49 (59.0) | ||
Female | 38 (39.2) | 49 (42.3) | 33 (39.8) | 34 (41.0) | ||
BMI (kg/m2, mean ± SD) | 24.7 ± 3.3 | 24.1 ± 3.3 | 0.254 | 24.6 ± 3.2 | 24.5 ± 3.3 | 0.935 |
ASA category | 0.027 | 1.000 | ||||
I-II | 89 (91.7) | 114 (98.3) | 81 (97.6) | 82 (98.8) | ||
III | 8 (8.3) | 2 (1.7) | 2 (2.4) | 1 (1.2) | ||
Distance from anal verge, median (range) cm | 4 (1–8) | 4 (1–8) | 0.113 | 4 (1–8) | 4 (1–8) | 0.486 |
CEA level (ng/ml) | 0.654 | 0.751 | ||||
≥5 | 41 (42.3) | 51 (44.0) | 32 (38.6) | 34 (41.0) | ||
<5 | 46 (57.7) | 65 (56.0) | 51(61.4) | 49 (59.0) | ||
LPN short-diameter before nCRT (cm, mean ± SD) | 1.3 ± 0.6 | 1.1 ± 0.5 | 0.103 | 1.2 ± 0.5 | 1.2 ± 0.6 | 0.930 |
Surgical approach | 0.025 | 0.787 | ||||
Open | 8 (8.2) | 22 (19.0) | 7 (8.4) | 8 (9.6) | ||
Laparoscopic | 89 (91.8) | 94 (81.0) | 76 (91.6) | 75 (90.4) | ||
Histology | 0.039 | 0.222 | ||||
Moderate | 76 (78.4) | 76 (65.5) | 64 (77.1) | 57 (68.7) | ||
Poor/Mucinous/signet | 21 (21.6) | 40 (34.5) | 19 (22.9) | 26 (31.3) | ||
Clinical T stage | 0.107 | 0.755 | ||||
T1 -T2 | 5 (5.2) | 8 (6.9) | 5 (6.0) | 6 (7.2) | ||
T3-T4 | 92 (94.8) | 108 (93.1) | 78 (94.0) | 77 (92.8) | ||
Clinical Mesenteric LN status | 0.191 | 0.360 | ||||
Positive | 85 (87.6) | 94 (81.0) | 66 (79.5) | 61 (73.5) | ||
Negative | 12 (12.4) | 22 (19.0) | 17 (20.5) | 22 (26.5) | ||
(y) Clinical T stage | - | - | ||||
T1-T2 | 26 (26.8) | - | 25 (30.1) | - | ||
T3-T4 | 71 (73.2) | - | 58 (69.9) | - | ||
(y) Clinical Mesenteric LN status | - | - | ||||
Positive | 54 (55.7) | - | 50 (60.2) | - | ||
Negative | 43 (44.3) | - | - | 33 (39.8) | - | |
LPN short-diameter after nCRT (cm, mean ± SD) | 0.7 ± 0.4 | - | 0.7 ± 0.3 | - | - | |
Type of operation | 0.792 | 0.759 | ||||
LAR | 44 (45.3) | 60 (51.7) | 38 (45.8) | 40 (48.2) | ||
APR | 44 (45.3) | 48 (41.4) | 37 (44.6) | 38 (45.8) | ||
Hartmann procedure | 6 (6.2) | 5 (4.3) | 5 (6.0) | 4 (4.8) | ||
TPE | 3 (3.1) | 3 (2.6) | 3 (3.6) | 1 (1.2) | ||
LPND | 0.473 | 0.310 | ||||
Bilateral | 32 (33.0) | 33 (28.4) | 28 (33.7) | 22 (26.5) | ||
Unilateral | 65 (67.0) | 83 (71.6) | 55 (66.3) | 61 (73.5) | ||
Adjuvant therapy | 79 (81.4) | 85 (73.3) | 0.158 | 65 (78.3) | 61 (73.5) | 0.468 |
Chemotherapy | 79 (81.4) | 73 (63.0) | 65 (78.3) | 51 (61.4) | ||
Chemoradiation + chemotherapy | 0 (0) | 12 (10.3) | 0 (0) | 10 (12.1) | ||
Mesorectal fascial involvement | 0.001 | 0.245 | ||||
Yes | 9 (9.3) | 0 (0) | 2 (2.4) | 0 (0) | ||
No | 88 (90.7) | 116 (100.0) | 81 (97.6) | 83 (100.0) | ||